The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up-Reference-Cited by-同舟云学术

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up

Published:2009-02 Issue:3 Volume:29 Page:286-297
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

LEES C. W.,ALI A. I.,THOMPSON A. I.,HO G.-T.,FORSYTHE R. O.,MARQUEZ L.,COCHRANE C. J.,AITKEN S.,FENNELL J.,ROGERS P.,SHAND A. G.,PENMAN I. D.,PALMER K. R.,WILSON D. C.,ARNOTT I. D. R.,SATSANGI J.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2008.03882.x/fullpdf

Reference34 articles.

1. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial;Colombel;Gastroenterology,2007

2. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

3. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial;Hanauer;Gastroenterology,2006

4. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial;Sandborn;Gut,2007

5. Infliximab maintenance therapy for fistulizing Crohn’s disease;Sands;N Engl J Med,2004

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased Risk of Cutaneous T‐Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis;Dermatologic Therapy;2024-01

2. Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review;Cancers;2023-07-27

3. Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review;American Journal of Clinical Dermatology;2023-01-10

4. Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery;Scandinavian Journal of Gastroenterology;2022-02-21

5. Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn’s Disease;Journal of Clinical Gastroenterology;2021-12-15